ALNYLAM PHARMACEUTICALS, INC. (ALNY) Stock Profile — Insider Trades & Financials

Revenue$1.1B

Net Income$186.4M

EPS$2.33

Market Cap$42.4B

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Yvonne Greenstreet

CEO & Executive Director

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

Employees: 2,100
Headquarters: CAMBRIDGE, MA, United States
Website: www.alnylam.com

Peer ComparisonRevenue ($B)

▾

⚡

Core Efficiency

ROE?

23.62%

ROA?

3.75%

D/E Ratio?

5.29

Op. Margin?

12.01%

📊

Profitability Ratios

Net Margin?

16.99%

Loading company sections...

ALNYLAM PHARMACEUTICALS, INC.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness